Navigation Links
Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
Date:10/29/2009

safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

    Table 1
                              Amicus Therapeutics, Inc.
                            (a development stage company)
                        Consolidated Statements of Operations
                                    (Unaudited)
                 (In thousands, except share and per share amounts)

                                                                 Period from
                                                                  February
                            Three Months         Nine Months       4, 2002
                               Ended                Ended      (inception) to
                            September 30,        September 30,   September 30,
                            -------------        ------------   -------------
                           2008       2009       2008      2009       2009
                           ----       ----       ----      ----       ----
    Revenue:
      Research revenue   $2,959     $4,219     $8,539    $12,799     $26,362
      Collaboration
       revenue              694        694      2,083      2,083       5,270
                            ---        ---      -----      -----       -----
    Total revenue         3,653      4,913     10,622     14,882      31,632
                          -----      -----     ------     ------      ------

    Operating Expenses:
      Research and
       development        8,200     12,609     23,989     37,954     165,596
      General and
       administrative     4,371      5,217     14,676     15,635      73,371
      Impairment of
       leasehold
       improvements           -          -          -          -       1,030
      Depreciation and
       amortization         382        561      1,036      1,585       5,872
      In-process research
       and development        -          -          -          -         418
                           
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project ... the legal requirements around using controlled substances in pharmaceutical ... As their international operations expand and become increasingly complex, ... as a result of the first phase of the ...
(Date:1/22/2015)... ALTO, Calif. , Jan. 22. 2015  Varian Medical Systems ... and software, has been honored for its commitment to sustainability ... sustainable companies. Varian is the highest ranked healthcare equipment company ... announced today during the World Economic Forum at ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 PlasmaTech ... care in critical areas, announced the closing of an underwritten ... to purchase up to an aggregate 3,500,000 shares of common ... $.01 per warrant.  The warrants have a per share exercise ...
(Date:12/24/2014)... MA (PRWEB) December 23, 2014 Earlier this ... L. Sherley, director of the Adult Stem Cell Technology Center, ... and under appreciated unique property of adult tissue stem cells. ... in the Past, Important for the Future,” embodied the essence ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... Internet sites to provide them with health maintenance information ... the University of Wisconsin-Milwaukee . And Milwaukee-based ... of the study, which aims to examine the factors ... influences people to trust the information provided when making ...
... banner ads, even when users aren't clicking, according to ... sponsored by Ask Jeeves, Google, ING, Lycos Search and ... environment works on two levels: paid click-thrus from active ... surfers. The study included advertising for leading health, auto, ...
... IT Fusion SOS (Small Office Solutions), a ... for its initial client group this month. The ... around an outsourced network management solution set, affording ... WAN, voice, data back-up, e-mail and Web site-hosting ...
Cached Biology Technology:eCare Solutions, UW Milwaukee to study health web sites 2Text ads deliver what you pay for - and more 2Text ads deliver what you pay for - and more 3
(Date:1/22/2015)... , Jan. 13, 2015 Technology Showcase, Hall E ... identity authentication solutions, today announced it will showcase its EyeLock ... developed by the Department of Energy,s Oak Ridge National ... Auto Show . EyeLock,s iris identity authentication technology is being ...
(Date:1/22/2015)...  Analyst Report Issued by Small Cap IR. In 2011, Nilson ... transactions at merchants on the leading payment cards rose to ... debit, and prepaid cards reached 6.54 billion.  Eight million credit ... usage in 2012, and credit and debit card fraud resulted ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, ... to eliminate the pain of trying to remember their usernames ... biometrics fused to their smartphones. To assist people who have ... the company that created 1U and focuses on redefining identity, ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
... for genetic diseases during in vitro fertilization offers couples ... genetic glitch could potentially cause doctors to misdiagnose a ... , Citing concerns about the accuracy of preimplantation ... the healthiest embryos during IVF, UF researchers set out ...
... a bid to facilitate collaboration among other biomolecular ... Laboratory has become the first institution outside the ... Consortium of Great Britain. , The BioSimGrid was ... Oxford, Southampton, Bristol, Birkbeck, Nottingham and York. Researchers ...
... lead is a well-known human health hazard, researchers at the ... of how it may work in mice to harm the ... bacteria, viruses and other bugs. , The discovery adds insight ... their emphasis from the immediate public health threat to understanding ...
Cached Biology News:Genetic testing still smart choice, despite uncertainties 2Genetic testing still smart choice, despite uncertainties 3Grid bridges 4,800 miles for molecular repositories 2The dangerous legacy of lead 2
Donor Horse Serum US Origin...
jub, ajuba homolog (Xenopus laevis)...
Size & Applications: 100 ul (2 mM). Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.) Storage Temp.: -20C Shelf Life: 6-12 month...
NM522 contains an F episome, which is required for production of ssDNA and for blue/white color selection. To maintain the F, NM522 should be grown on minimal (M-9) medium....
Biology Products: